EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 352 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR New on NCI’s Websites for August 2024 August 16, 2024 Intercontinental Asian Study Compiles the Relative Incidence of non-Hodgkin T-cell Lymphoma... November 21, 2020 Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive... July 2, 2025 Five Questions with…Debra. March 31, 2022 Load more HOT NEWS Cancer in My Community: Overcoming Delays in Care for Children With... Twins Born 15 Minutes Apart Have Birthdays In Different Years Dad Gets Tattoo On His Chest To Match Daughter’s Scar So... How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy
